Literature DB >> 26535020

Pharmaceutical Approval Update.

Kunj Gohil.   

Abstract

Alirocumab (Praluent) for high cholesterol; flibanserin (Addyi) for sexual desire disorder in women; daclatasvir (Daklinza) for chronic hepatitis C virus (HCV) genotype 3 infection; and ombitasvir/paritaprevir/ritonavir (Technivie) for genotype 4 HCV infection without cirrhosis.

Entities:  

Year:  2015        PMID： 26535020      PMCID： PMC4606854     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  2 in total

1.  Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.

Authors:  Anita H Clayton; Stanley E Althof; Sheryl Kingsberg; Leonard R DeRogatis; Robin Kroll; Irwin Goldstein; Jed Kaminetsky; Carl Spana; Johna Lucas; Robert Jordan; David J Portman
Journal:  Womens Health (Lond)       Date:  2016-05-16

2.  Twitter As a Noninvasive Bio-Marker for Trends in Liver Disease.

Authors:  Ben L Da; Pallavi Surana; Samuel A Schueler; Niloofar Y Jalaly; Natasha Kamal; Sonia Taneja; Anusha Vittal; Christy L Gilman; Theo Heller; Christopher Koh
Journal:  Hepatol Commun       Date:  2019-07-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.